Expression and function of CD59 on colonic adenocarcinoma cells

European Journal of Immunology
L BjørgeR Matre

Abstract

The expression and function of CD59, a 19-25 kDa membrane glycoprotein that inhibits formation of the membrane attack complex of complement, was analyzed on normal and malignant human colonic epithelial cells. Analysis by immunofluorescence demonstrated a weak apical expression of CD59 on normal intestinal epithelium, with an increased expression on adenocarcinoma cells. The expression of CD59 was greatest on tumor cells with poor differentiation. The functional activity of CD59 on human adenocarcinoma cells was investigated using the colonic adenocarcinoma cell line HT29. CD59 on HT29 cells was glycosyl-phosphatidylinositol-linked, and had a molecular mass of 19-25 kDa. HT29 cells expressed approximately four times more CD59 than leukocytes, and showed a high resistance to antibody-dependent complement-mediated lysis. Blocking of CD59 with divalent antigen-binding F(ab')2 fragments of the anti-CD59 monoclonal antibody 1F5 resulted in a dose-dependent increase in complement-mediated lysis, suggesting that CD59 may be of importance in protecting colonic adenocarcinoma cells against complement-mediated cytolysis.

References

Nov 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·D T Fearon
Nov 1, 1992·Tissue Antigens·L A WalshH Waldmann
Nov 1, 1992·European Journal of Immunology·M DeckertA Bernard
Nov 1, 1992·Trends in Biochemical Sciences·A M Tartakoff, N Singh
Sep 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·L S ZalmanH J Müller-Eberhard
Apr 1, 1988·The Journal of Clinical Investigation·N K CheungM E Medof
May 1, 1993·Immunology Letters·L BjørgeR Matre

❮ Previous
Next ❯

Citations

Mar 4, 2000·Molecular Immunology·K JurianzM Kirschfink
Apr 22, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C A SchmittW G Dippold
Apr 1, 1996·The Journal of Experimental Medicine·M J MaeurerM T Lotze
Jun 1, 1995·Immunological Reviews·G J FleurenS O Warnaar
Jan 1, 1995·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·P Brandtzaeg
Nov 10, 1998·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·L ThorsteinssonP M Johnson
May 29, 2002·Molecular Pathology : MP·T InoueT Takahashi
Jun 29, 2004·Journal of Translational Medicine·Ester FonsattiMichele Maio
May 30, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R OkaK Saijoh
May 26, 1998·Journal of Neuroimmunology·N J ScoldingD A Compston
Jun 14, 2002·Neuromuscular Disorders : NMD·Mathias MäurerRalf Gold
Jan 20, 2007·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Naren M H Ravindranath, Charles Shuler
Jan 10, 2008·International Journal of Cancer. Journal International Du Cancer·Ewa WilczekGrzegorz M Wilczynski
Feb 1, 1996·Baillière's Clinical Rheumatology·P Brandtzaeg
Sep 15, 1998·The American Journal of Pathology·J Hakulinen, S Meri
Feb 24, 2005·British Journal of Cancer·L BjørgeS Meri
Jul 17, 1999·Journal of Cutaneous Pathology·M WeichenthalE W Breitbart
Sep 14, 2006·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Naren M H Ravindranath, Charles Shuler
Jun 7, 2003·Scandinavian Journal of Immunology·V T BlokA Gorter
Nov 11, 2020·Antibodies·Joshua M ThurmanRaphael A Nemenoff
Sep 7, 2000·Biochemical and Biophysical Research Communications·G BahrenbergG Jakse

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.